Radiation, chemotherapy, and immunotherapy for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Rectal cancer confirmed by biopsy, located within 12 cm of the anus
- Cancer is advanced (stage T3–T4 or has spread to lymph nodes) but not spread to distant organs
- Good overall health and blood counts, liver, and kidney function
- No previous chemotherapy or immunotherapy for rectal cancer
- No active autoimmune disease, serious lung disease, or uncontrolled diabetes/high blood pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial studies a shorter course of radiation for rectal cancer, followed by chemotherapy and an immune treatment called a PD-1 inhibitor. It aims to improve treatment outcomes for people with locally advanced rectal cancer that has not spread to distant organs.
This trial tests adding two new drugs—tafolecimab and sintilimab—to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination shrinks tumors more effectively and helps patients avoid a permanent colostomy.
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
This Phase 2 trial studies whether adding sintilimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with locally advanced rectal cancer. It’s aimed at tumors with certain immune “signature” scores and specific cancer stage features.
This trial tests a combination of short-course radiation, chemotherapy (CAPOX), and an immunotherapy drug (PD-1 inhibitor) for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.